EN DE
Watch Respiratorius AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Respiratorius AB (RESP) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Respiratorius AB stock SEK 0.93, price SEK 1.36, that is 31.6% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE

RA Respiratorius AB logo Thin data Nov 10, 2026

Respiratorius AB

RESP · ST
Expensive, weak quality

Our calculation puts a fair price 32% below what the stock costs today.

Ranks above peers (5/6)
Quality 44/100
Fair value kr 0.9300 · Overvalued
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Respiratorius AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 114.73 kr 1.24 Fair Value kr 0.9300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 1.24 – kr 114.73 · fair‑value band kr 0.7000 – kr 1.16 · the kr 1.36 price screens above the kr 0.9300 fair value. As of Nov 10, 2026.

Follow Respiratorius in your weekly email

Every Wednesday you see whether Respiratorius is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer.

Show moreShow less

The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma.

Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

Stock analysis

Respiratorius AB (RESP) currently trades at kr 1.36, while our estimate is kr 0.9300, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.7000 (bear) to kr 1.16 (bull), the price of kr 1.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Respiratorius AB reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2023. Reported net income was −7.0M SEK in FY2025.

Key figures

Market cap 17.1M SEK (≈ $1.7M) Micro · EPS (TTM) kr −0.8400 · Return on equity −24.9% · Return on assets (EBIT) −24.7% (3-year average) · Operating margin −22,116% · Revenue (TTM) 30.1K SEK · Free cash flow −7.8M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, RESP screens richer than that median.

Fair Value

Bear kr 0.7000 Fair Value kr 0.9300 Bull kr 1.16
Price kr 1.36 · Downside -31.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 63
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 5
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

RESP screens overvalued: fair value 32% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Respiratorius AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside −31.6% · Below median
Profitability
Return on assets −21.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.56× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs RESP
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs RESP
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs RESP
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs RESP
argenx SE ARGX $977.58 $908.40 −7% vs RESP
CSL Limited CSL A$204.54 A$181.40 −11% vs RESP
Moderna, Inc MRNA $248.69 $158.70 −36% vs RESP
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs RESP
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs RESP
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs RESP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Respiratorius AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Respiratorius AB Fair Value". https://www.fairvalue-calculator.com/stock/RESP

Frequently asked questions

Is Respiratorius AB (RESP) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.9300 versus a price of kr 1.36, about 32% lower (overvalued).
What is the fair value of RESP?
Our estimate for Respiratorius AB is kr 0.9300 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 1.36.
What is the quality score of RESP?
Respiratorius AB has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Respiratorius AB (RESP)?
Our calculated price target is the estimate of kr 0.9300 (as of Nov 10, 2026). Cautious scenario kr 0.7000, optimistic scenario kr 1.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Respiratorius AB stock forecast for 2026?
Our estimate puts fair value at kr 0.9300, about 32% lower versus a price of kr 1.36 (overvalued). Cautious scenario kr 0.7000, optimistic scenario kr 1.16. The calculation is refreshed regularly with new filings.
What is the revenue of Respiratorius AB (RESP)?
Respiratorius AB reported trailing-twelve-month revenue of about 30.1K SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Respiratorius AB (RESP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Respiratorius AB it is kr 0.9300 per share (as of Nov 10, 2026), against a price of kr 1.36.
Is Respiratorius AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, RESP trades above its calculated fair value: price kr 1.36, fair value kr 0.9300, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RESP?
No. The price is what the market pays today (kr 1.36); the fair value is what the company's own numbers justify (kr 0.9300). For Respiratorius AB the two are kr 0.4300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Respiratorius AB worth?
The market values Respiratorius AB at about 17.1M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 1.36; our models calculate a fair value of kr 0.9300 per share.
What do the bullish and bearish scenarios say about RESP?
Our models span a range for Respiratorius AB: cautious scenario kr 0.7000, base kr 0.9300, optimistic kr 1.16 per share (as of Nov 10, 2026, price kr 1.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Respiratorius AB (RESP)?
Balance-sheet figures for Respiratorius AB (as of Nov 10, 2026): return on equity −24.9%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is RESP from its 52-week high?
Respiratorius AB trades at kr 1.36, about 59% below its 52-week high of kr 3.33 and 10% above the low of kr 1.24 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.9300 is for.
Which stocks are comparable to Respiratorius AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Respiratorius AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 1.36, calculated fair value kr 0.9300 (−32%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Respiratorius AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Respiratorius AB (RESP)?
The closing price on Nov 11, 2026 was kr 1.36. Our estimate is kr 0.9300, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Respiratorius AB right now?
The price sits above even our optimistic bull case (kr 1.16). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Respiratorius AB

How large is the market capitalisation of Respiratorius AB (RESP)?
The market capitalisation of Respiratorius AB is 17.1M SEK (≈ $1.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Respiratorius AB (RESP)?
Earnings per share at Respiratorius AB are kr −0.8400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Respiratorius AB (RESP)?
The return on equity (ROE) of Respiratorius AB is −24.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Respiratorius AB (RESP)?
On an EBIT basis the return on assets of Respiratorius AB is −24.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Respiratorius AB (RESP)?
The operating margin of Respiratorius AB is −22,116% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Respiratorius AB (RESP) generate?
The free cash flow of Respiratorius AB is −7.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Respiratorius AB in the live analysis

One click puts Respiratorius AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.